Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | MET | P08581 | 10/20 | 0.49 |
| ▸ | AXL | P30530 | 8/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | MERTK | Q12866 | 3/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | HCK | P08631 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18542898 | 0.94 | EGFR (0.47) | EGFRMETAXLKDRMERTK | |
| SCHEMBL12468984 | 0.86 | ALDH1A1 (0.53) | EGFRMETAXLKDRMERTK | |
| SCHEMBL27952824 | 0.85 | ALDH1A1 (0.47) | EGFRMAOAALDH1A1NPC1RAB9A | |
| SCHEMBL374160 | 0.85 | MAPT (0.56) | EGFRMETAXLKDRMERTK | |
| SCHEMBL16136596 | 0.84 | EGFR (0.62) | EGFRMETAXLKDRMERTK | |
| SCHEMBL23755859 | 0.84 | EGFR (0.41) | EGFRMETAXLKDRMERTK | |
| SCHEMBL18542894 | 0.84 | CA12 (0.41) | EGFR | |
| SCHEMBL143909 | 0.83 | TSHR (0.50) | ALDH1A1NPC1RAB9AMEN1HTT | |
| SCHEMBL13271309 | 0.83 | ALDH1A1 (0.50) | EGFRMETAXLKDRMERTK | |
| SCHEMBL19370182 | 0.83 | MET (0.46) | EGFRMETAXLKDRMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188776-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CABOZANTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | NATCO PHARMA LIMITED (IN) | 2021-06-24 | — | — | US | claimed |
| CN-111217745-B | Preparation method of cabozantinib | 漯河医学高等专科学校 | 2021-05-11 | — | — | CN | claimed |
| CN-111217745-A | Preparation method of cabozantinib | 漯河医学高等专科学校 | 2020-06-02 | — | — | CN | claimed |
| CN-116655626-A | Cyclopropanamide compound containing imidazo [ l,2-a ] pyridine skeleton and preparation method and application thereof | 遵义医科大学 | 2023-08-29 | — | — | CN | disclosed |
| CN-114907339-B | 4- (4-aminophenoxy) pyridin-2-amine derivatives and use thereof | 成都奥睿药业有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-11498902-B2 | Process for the preparation of Cabozantinib and its pharmaceutically acceptable salts thereof | NATCO PHARMA LIMITED (IN) | 2022-11-15 | — | — | US | disclosed |
| CN-114907339-A | 4- (4-aminophenoxy) pyridin-2-amine derivatives and uses thereof | 成都奥睿药业有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-109988108-B | Preparation method of cabozantinib | 江苏豪森药业集团有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20220089541-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2022-03-24 | — | — | US | disclosed |
| CN-113710322-A | Compounds for the treatment of kinase-dependent disorders | 埃克塞里艾克西斯公司 | 2021-11-26 | — | — | CN | disclosed |
| US-20210188776-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CABOZANTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | NATCO PHARMA LIMITED (IN) | 2021-06-24 | — | — | US | disclosed |
| US-20120322834-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322834-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120252849-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHAMACEUTICALS, LLC (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252849-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHAMACEUTICALS, LLC (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252849-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHAMACEUTICALS, LLC (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120058985-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058985-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058985-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2011137342-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252849-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 1362/4885MET 2169/4885AXL 4475/4885 |
| US-20210188776-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CABOZANTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | FIP1L1, FGFR1, RCC1 | EGFR 234/4885MET 619/4885AXL 334/4885 |
| US-20120322834-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 1362/4885MET 2169/4885AXL 4475/4885 |
| US-20220089541-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | PRKDC, MAP3K20, BRAF | EGFR 573/4885MET 367/4885AXL 1643/4885 |
| US-20120058985-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 1362/4885MET 2169/4885AXL 4475/4885 |
| US-11498902-B2 | Process for the preparation of Cabozantinib and its pharmaceutically acceptable salts thereof | FIP1L1, ABL1, FGFR1 | EGFR 206/4885MET 597/4885AXL 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.